Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1980 1
1982 3
1983 2
1984 1
1987 1
1989 3
1991 1
1992 1
1993 3
1994 2
1998 1
1999 3
2000 6
2001 3
2002 8
2003 2
2004 4
2005 2
2006 2
2007 2
2008 2
2010 2
2011 2
2012 2
2013 1
2014 1
2017 1
2018 1
2019 4
2020 2
2021 1
2022 3
2023 5
2024 4
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Pectoralis major radiation recall.
Hack E, Thachil T, Karanth N. Hack E, et al. Among authors: karanth n. J Med Radiat Sci. 2019 Mar;66(1):62-65. doi: 10.1002/jmrs.303. Epub 2018 Sep 9. J Med Radiat Sci. 2019. PMID: 30198200 Free PMC article.
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary.
Rebello RJ, Posner A, Dong R, Prall OWJ, Sivakumaran T, Mitchell CB, Flynn A, Caneborg A, Mitchell C, Kanwal S, Fedele C, Webb S, Fisher K, Wong HL, Balachander S, Zhu W, Nicolson S, Dimitriadis V, Wilcken N, DeFazio A, Gao B, Singh M, Collins IM, Steer C, Warren M, Karanth N, Xu H, Fellowes A, Hicks RJ, Stewart KP, Shale C, Priestley P, Dawson SJ, Vissers JHA, Fox SB, Schofield P, Bowtell D, Hofmann O, Grimmond SM, Mileshkin L, Tothill RW. Rebello RJ, et al. Among authors: karanth n. Nat Commun. 2025 May 20;16(1):4422. doi: 10.1038/s41467-025-59661-x. Nat Commun. 2025. PMID: 40393956 Free PMC article.
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.
Tie J, Wang Y, Loree JM, Cohen JD, Wong R, Price T, Tebbutt NC, Gebski V, Espinoza D, Burge M, Harris S, Lynam J, Lee B, Lee MM, Breadner D, Debrincat M, Foroughi S, Chantrill L, Lim SH, Gill S, O'Callaghan C, Ptak J, Silliman N, Dobbyn L, Popoli M, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P; AGITG DYNAMIC-III Study Group (Intergroup Study of the Australasian Gastro-Intestinal Trials Group and Canadian Cancer Trials Group). Tie J, et al. Nat Med. 2025 Oct 20. doi: 10.1038/s41591-025-04030-w. Online ahead of print. Nat Med. 2025. PMID: 41115959
Development of a biosensor for caffeine.
Babu VR, Patra S, Karanth NG, Kumar MA, Thakur MS. Babu VR, et al. Among authors: karanth ng. Anal Chim Acta. 2007 Jan 23;582(2):329-34. doi: 10.1016/j.aca.2006.09.017. Epub 2006 Sep 27. Anal Chim Acta. 2007. PMID: 17386510
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A, Sivakumaran T, Pattison A, Etemadmoghadam D, Thio N, Wood C, Fisher K, Webb S, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, Collins IM, Richardson G, Steer C, Warren M, Karanth N, Fellowes A, Fox SB, Hicks RJ, Schofield P, Bowtell D, Prall OWJ, Tothill RW, Mileshkin L. Posner A, et al. Among authors: karanth n. J Immunother Cancer. 2023 Jan;11(1):e005809. doi: 10.1136/jitc-2022-005809. J Immunother Cancer. 2023. PMID: 36720497 Free PMC article.
Microbial production of oligosaccharides: a review.
Prapulla SG, Subhaprada V, Karanth NG. Prapulla SG, et al. Among authors: karanth ng. Adv Appl Microbiol. 2000;47:299-343. doi: 10.1016/s0065-2164(00)47008-5. Adv Appl Microbiol. 2000. PMID: 12876801 Review. No abstract available.
80 results